Chronic toxicity of a new synthetic corticosteroid, hydrocortisone 17-butyrate 21-propionate (HBP), was investigated in rats of both sexes. HBP was percutaneously given to rats with 0.1%, 0.5% cream and ointment at the daily dose level of 150 mg per 100 g body weight for 6 months. For the comparison, the percutaneous toxicity with 0.12% betamethasone 17-valerate (BV) cream and ointment, and 0.1% hydrocortisone 17-butyrate (HB) cream and ointment at the daily dose level of 150 mg per 100 g body weight were studied. Rats receiving HBP showed the dose-dependent changes such as the suppression of body weight gain and food intake, emaciation, decrease in the number of white blood cells and lymphocytes, total protein, increase in the number of red cells, hematocrit, hemoglobin, blood sugar and total cholesterol, regressive changes in adrenal cortex, lymphatic and hematopoietic tissues and skin, and gastric erosion, which have been well known as toxic effects of synthetic corticosteroids. These findings were comparatively high toxic in male, and almost disappeared in rats elapsed recovery time of month after withdrawal of HBP. The toxicities of HBP, BV and HB were qualitatively same. However, the grade of effects of HBP toxicity was similar to that of HB, weaker than of BV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2131/jts.6.supplement_97 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic Identification of Copositivity Groups in Standard Series Patch Testing Through Hierarchical Clustering.
JAMA Dermatol
September 2023
Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
Article Synopsis
- Patients can be sensitized to multiple allergens simultaneously, making it important to identify these "copositivity groups" for better contact avoidance.
- A study analyzed data from 5943 patients at the Mayo Clinic to determine copositivity rates among 80 allergens, using hierarchical clustering to reveal distinct groups.
- Results showed that many identified copositivity groups matched previous findings, while new associations were also discovered, enhancing understanding of how different allergens may relate to each other.
Contact allergy to corticosteroids: Is the European baseline series sufficient?
Contact Dermatitis
October 2023
Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense C, Denmark.
Background: Patients are consecutively screened for contact allergy to corticosteroids with budesonide and tixocortol-21-pivalate in the European baseline series. Centres using TRUE Test also include hydrocortisone-17-butyrate. A supplementary corticosteroid patch test series is used in case of suspicion of corticosteroid contact allergy or when a marker of corticosteroid contact allergy is positive.
View Article and Find Full Text PDFThe Contest of Nanoparticles: Searching for the Most Effective Topical Delivery of Corticosteroids.
Pharmaceutics
February 2023
Department of Organic Technology, Faculty of Chemical Technology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic.
Owing to their complicated pathophysiology, the treatment of skin diseases necessitates a complex approach. Conventional treatment using topical corticosteroids often results in low effectiveness and the incidence of local or even systemic side effects. Nanoformulation of potent anti-inflammatory drugs has been selected as an optimal strategy for enhanced topical delivery of corticosteroids.
View Article and Find Full Text PDFPrevalence of contact allergy to corticosteroids in a Danish patient population.
Contact Dermatitis
September 2022
Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Background: Allergic contact dermatitis to corticosteroids can be a challenging diagnosis as corticosteroids are used in the treatment of dermatitis. The prevalence of contact allergy to corticosteroid varies between previous studies.
Objective: To study the prevalence of sensitization to budesonide, tixocortol-21-pivalate and hydrocortisone-17-butyrate in a Danish patient population from 2006-2020, cross-sensitization, risk factors and clinical relevance.
Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
Eur J Dermatol
December 2021
Helsinki University Hospital, Department of Dermatology and Allergology, Meilahdentie 2, 00250 Helsinki, Finland.
Background: Atopic dermatitis (AD) has a severe impact on quality of life (QoL).
Objectives: To analyze the impact of AD on QoL of small children with moderate-to-severe AD in a tertiary health care hospital in Helsinki, Finland.
Materials & Methods: Based on interim analysis of this longitudinal follow-up study, we investigated treatment response (topical corticosteroids vs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!